ARTICLE | Management Tracks
New roles for Sheridan, Arnold at BioCryst
Plus Maltais joins XNK as CSO, and updates from HaYa, Ratio and more
September 15, 2022 11:00 PM UTC
Rare disease company BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) named CMO Bill Sheridan chief development officer. SVP of Global Medical Affairs Ryan Arnold becomes CMO.
XNK Therapeutics AB hired Anna-Karin Maltais as CSO, effective Oct. 17. Maltais was head of CMC, biotech research and product development, global rare diseases at Chiesi Farmaceutici S.p.A. XNK is developing NK cell therapies for cancer. ...